Business Context and Reporting Period
This Form 6-K filing by Regencell Bioscience Holdings Ltd covers the month of June 2025, specifically dated June 2, 2025. The report announces a corporate action regarding a forward stock split approved by the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the mechanics of a stock split and does not contain financial performance data.
Material Changes
- Stock Split: A 38-for-one forward stock split was approved to be paid as a stock bonus.
- Shareholder Impact: Shareholders of record at the close of business on June 12, 2025, will receive 37 additional shares for every share held.
- Capital Structure: Outstanding shares will increase at the split ratio, while authorized share capital and par value remain unchanged.
- Trading Details: The Company's name, CUSIP, and trading symbol will remain unchanged. Trading on a post-split basis is expected to begin at market open on June 16, 2025, subject to Nasdaq Capital Market approval.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard requirement for Nasdaq approval of the split. No unusual items or contingencies are disclosed in this text.
Investor Verification Checklist
- Confirm the record date of June 12, 2025, to ensure eligibility for the stock bonus.
- Verify the distribution date of June 13, 2025, for the receipt of additional shares.
- Monitor Nasdaq Capital Market approval status to confirm the June 16, 2025, trading start date.
- Check brokerage account statements to ensure automatic adjustment of holdings for the 38-for-one split.